Evidence map›Paper›PMID 28424685›Full record

ArticleFrontiers in immunology2017

Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome.

Eszter Trojnár, Mihály Józsi, Katalin Uray, Dorottya Csuka, Ágnes Szilágyi, Danko Milosevic, Vesna D Stojanović, Brankica Spasojević, Krisztina Rusai, Thomas Müller and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Assessment of the Role of C3(HFrontiers in immunology · 2020
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 5 countries.

Eszter Trojnár3rd Department of Internal Medicine, Research Laboratory, Semmelweis University, Budapest, Hungary.
Mihály JózsiMTA-ELTE "Lendület" Complement Research Group, Department of Immunology, Eötvös Loránd University, Budapest, Hungary.
Katalin UrayMTA-ELTE Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Eötvös Loránd University, Budapest, Hungary.
Dorottya Csuka3rd Department of Internal Medicine, Research Laboratory, Semmelweis University, Budapest, Hungary.
Ágnes Szilágyi3rd Department of Internal Medicine, Research Laboratory, Semmelweis University, Budapest, Hungary.
Danko MilosevicDepartment of Pediatric Nephrology, Dialysis and Transplantation, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia.
Vesna D StojanovićMedical Faculty, Institute for Child and Youth Health Care of Vojvodina, University of Novi Sad, Novi Sad, Serbia.
Brankica SpasojevićUniversity Children's Hospital, Nephrology, Dialysis and Transplantation Unit, Belgrade, Serbia.
Krisztina RusaiDepartment of Pediatrics, Medical University of Vienna, Vienna, Austria.
Thomas MüllerDepartment of Pediatrics, Medical University of Vienna, Vienna, Austria.
Klaus ArbeiterDepartment of Pediatrics, Medical University of Vienna, Vienna, Austria.
Kata Kelen1st Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Attila J Szabó1st Department of Pediatrics, Semmelweis University, Budapest, Hungary.
György S Reusz1st Department of Pediatrics, Semmelweis University, Budapest, Hungary.
Satu HyvärinenResearch Programs Unit, Immunobiology, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland.
T Sakari JokirantaResearch Programs Unit, Immunobiology, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland.
Zoltán Prohászka3rd Department of Internal Medicine, Research Laboratory, Semmelweis University, Budapest, Hungary.
Semmelweis University · HUMedical University of Vienna · ATEötvös Loránd University · HUHelsinki University Hospital · FIHungarian Academy of Sciences · HUInstitute of Public Health of Vojvodina · RSUniversity Children's Hospital, Belgrade · RSUniversity of Helsinki · FIUniversity of Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn autoimmune atypical hemolytic uremic syndrome (aHUS), the complement regulator factor H (FH) is blocked by FH autoantibodies, while 90% of the patients carry a homozygous deletion of its homolog complement FH-related protein 1 (CFHR1). The functional consequence of FH-blockade is widely established; however, the molecular basis of autoantibody binding and the role of CFHR1 deficiency in disease pathogenesis are still unknown. We performed epitope mapping of FH to provide structural insight in the autoantibody recruitment on FH and potentially CFHR1.

methodsEight anti-FH positive aHUS patients were enrolled in this study. With overlapping synthetic FH and CFHR1 peptides, we located the amino acids (aa) involved in binding of acute and convalescence stage autoantibodies. We confirmed the location of the mapped epitopes using recombinant FH domains 19-20 that carried single-aa substitutions at the suspected antibody binding sites in three of our patients. Location of the linear epitopes and the introduced point mutations was visualized using crystal structures of the corresponding domains of FH and CFHR1.

resultsWe identified three linear epitopes on FH (aa1157-1171; aa1177-1191; and aa1207-1226) and one on CFHR1 (aa276-290) that are recognized both in the acute and convalescence stages of aHUS. We observed a similar extent of autoantibody binding to the aHUS-specific epitope aa1177-1191 on FH and aa276-290 on CFHR1, despite seven of our patients being deficient for CFHR1. Epitope mapping with the domain constructs validated the location of the linear epitopes on FH with a distinct autoantibody binding motif within aa1183-1198 in line with published observations. SUMMARY: According to the results, the linear epitopes we identified are located close to each other on the crystal structure of FH domains 19-20. This tertiary configuration contains the amino acids reported to be involved in C3b and sialic acid binding on the regulator, which may explain the functional deficiency of FH in the presence of autoantibodies. The data we provide identify the exact structures involved in autoantibody recruitment on FH and confirm the presence of an autoantibody binding epitope on CFHR1.

Indexed as

atypical hemolytic uremic syndromeCFHR1complement factor Hepitope mappingfactor H autoantibody

Identifiers

PMID28424685
PMCPMC5371605
OpenAlexW2600057717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.